Adverum Biotechnologies Q2 2024 Adj EPS $(0.89) Beats $(1.47) Estimate
Portfolio Pulse from Benzinga Newsdesk
Adverum Biotechnologies (NASDAQ:ADVM) reported a Q2 2024 adjusted EPS of $(0.89), beating the analyst consensus estimate of $(1.47) by 39.46%.
August 12, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adverum Biotechnologies reported a Q2 2024 adjusted EPS of $(0.89), significantly beating the analyst consensus estimate of $(1.47) by 39.46%.
The significant beat on earnings per share (EPS) compared to analyst estimates is likely to positively impact the stock price in the short term as it indicates better-than-expected financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100